Answers are grounded in this paper and cite their sources.
AD (Alzheimer's disease) is characterized neuropathologically by the presence of amyloid plaques, neurofibrillary tangles and profound grey matter loss. The 'amyloid' hypothesis postulates that the toxic Abeta (amyloid beta) peptide, enzymatically derived from the proteolytic processing of a larger protein called APP (amyloid precursor protein), is one of the principal causative factors of neuronal cell death in the brains of AD patients. As such, methods for lowering Abeta levels in the brain are of significant interest with regard to identifying novel disease modifying therapies for the treatment of AD. In this review, we will review a variety of approaches and mechanisms capable of modulating levels of Abeta.
No takes yet. Share an insight, caveat, or question.
Pangalos et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: